Compass Therapeutics Q4 EPS $(0.11) Misses $(0.09) Estimate
Portfolio Pulse from Happy Mohamed
Compass Therapeutics (CMPX) reported a Q4 EPS loss of $(0.11), missing the consensus estimate of $(0.09) by 22.22%. This represents a 10% increase in losses compared to the same period last year.
March 21, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Compass Therapeutics reported a larger than expected Q4 loss, missing analyst estimates and showing increased losses year-over-year.
Missing the consensus estimate by 22.22% and reporting increased losses compared to the previous year are negative indicators that could lead to decreased investor confidence and potentially lower stock prices in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100